Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature.

Claire C Yang Natalie Rosenwasser Xing Wang Zheng XuJoshua ScheckMarkus D Boos Deepti Gupta Heather A Brandling-Bennett Robert SidburyRamesh S IyerYongdong Zhao

Published in: Paediatric drugs (2023)

In our experience, golimumab has been shown to be a safe and effective therapy for CRMO and demonstrated improvement in paradoxical psoriasis in many patients. Longer follow-up periods would be helpful to develop longer term outcomes data for patients with CRMO and overall paradoxical psoriasis risk.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
ankylosing spondylitis
prognostic factors
preterm infants
ulcerative colitis
type diabetes
systemic lupus erythematosus
patient reported outcomes
machine learning
metabolic syndrome
gestational age
drug induced
hidradenitis suppurativa